Sold Record Number of Annual EksoHealth Units in 2023 SAN RAFAEL, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2023. Recent Highlights and Accomplishments Achieved record revenue of $18.3 million for the 2023 full year, an increase of 42% year-over-yearSold a total of 151 EksoHealth units for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Nevada 99-0 ...

The price trend for Ekso Bionics (EKSO) has been bearish lately and the stock has lost 8.9% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street ana ...

Ekso Bionics (NASDAQ:EKSO) stock is on the rise Friday without any clear news from the exoskeleton company this morning.There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today. On that same note, no analysts have offered coverage of the stock today that would have EKSO shares climbing higher.The only recent news worth noting about EKSO stock comes from an analyst update on Monday. H.C. Wainwright analysts increased the price target ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2023 Earnings Call October 26, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics Quarter Three 2023 Financial Results Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-036 ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q2 2023 Results Conference Call July 27, 2023 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Scott Davis - Chief Executive Officer Jason Jones - Chief Operating Officer Jerome Wong - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Hello, and welcome to the Ekso Bionics Q2 2023 Financial Results Conference Call and Webcast [Operator Instructions]. As a reminder, this conference is being recorded. It's now ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section details the company's financial performance, condition, and management's analysis, market risks, and internal controls [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The financial statements show increased revenue, widened net losses, decreased cash, and a disclosed substantial doubt about going concern [Condensed Consolidated Financial Statements](index=4&type=section&id=Condensed%20Consolidated%20Financial%20Statements) The unaudited statements show increased revenue and net loss, with cash significantly decreasing due to operational usage Condensed Consolidated Balance Sheet Highlights (in thousands) | Metric | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Cash and restricted cash | $13,307 | $20,525 | | Total current assets | $24,720 | $31,037 | | Total assets | $33,986 | $40,903 | | Total current liabilities | $10,129 | $9,201 | | Total liabilities | $16,179 | $15,461 | | Total stockholders' equity | $17,807 | $25,442 | Condensed Consolidated Statement of Operations Highlights (in thousands, except per share) | Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $4,703 | $3,465 | $8,825 | $6,032 | | Gross profit | $2,254 | $1,641 | $4,254 | $2,850 | | Loss from operations | $(4,284) | $(3,229) | $(8,732) | $(7,466) | | Net loss | $(4,230) | $(2,978) | $(8,619) | $(7,598) | | Net loss per share | $(0.31) | $(0.23) | $(0.64) | $(0.59) | Condensed Consolidated Statement of Cash Flows Highlights (in thousands) | Metric | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | $(7,117) | $(8,454) | | Net decrease in cash | $(7,218) | $(8,494) | | Cash and restricted cash at end of period | $13,307 | $31,912 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the HMC acquisition, debt obligations, segment revenue, and the critical going concern disclosure due to recurring losses - The company has concluded that **substantial doubt** exists about its ability to continue as a going concern for at least 12 months from the issuance date of the financial statements, citing historical operating losses, negative cash flows, and the need for additional funding[23](index=23&type=chunk) - On December 5, 2022, the company acquired the Human Motion and Control (HMC) Business Unit for **$9.055 million**, adding the Ekso Indego product line[19](index=19&type=chunk)[53](index=53&type=chunk)[57](index=57&type=chunk) Revenue by Segment (in thousands) | Segment | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | EksoHealth | $8,684 | $5,109 | | EksoWorks | $141 | $923 | | **Total** | **$8,825** | **$6,032** | - The company has a **$2.0 million term loan** maturing August 13, 2023, and a **$5.0 million promissory note** with quarterly payments of **$313k** starting December 31, 2023[82](index=82&type=chunk)[88](index=88&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=34&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses revenue growth, increased operating expenses from the HMC acquisition, and significant liquidity concerns reinforcing going concern risk [Results of Operations](index=39&type=section&id=Results%20of%20Operations) Q2 2023 revenue increased 36% driven by EksoHealth, but operating expenses rose 34% due to HMC acquisition, widening the loss from operations Q2 2023 vs Q2 2022 Performance (in thousands) | Metric | Q2 2023 | Q2 2022 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Revenue | $4,703 | $3,465 | $1,238 | 36% | | Gross Profit | $2,254 | $1,641 | $613 | 37% | | Gross Margin | 48% | 47% | - | - | | Total Operating Expenses | $6,538 | $4,870 | $1,668 | 34% | | Loss from Operations | $(4,284) | $(3,229) | $(1,055) | 33% | - **EksoHealth revenue increased** due to higher EksoNR and Indego device sales, while **EksoWorks revenue decreased** from lower EVO sales volume[188](index=188&type=chunk) - Operating expenses increased across all categories, including Sales and marketing (**+28%**), R&D (**+60%**), and General and administrative (**+29%**), primarily due to **HMC acquisition headcount and integration costs**[191](index=191&type=chunk)[192](index=192&type=chunk)[193](index=193&type=chunk) [Liquidity and Capital Resources](index=42&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity weakened with cash falling to **$13.3 million**, deemed sufficient only into Q2 2024, reinforcing substantial doubt about future cash requirements without additional financing - As of June 30, 2023, the company had **$13.3 million in cash**, with **$2.0 million restricted**, leaving **$11.3 million in unrestricted cash**[208](index=208&type=chunk)[209](index=209&type=chunk) - Management concluded that **$13.3 million in cash** is sufficient only into Q2 2024, and **substantial doubt exists** about meeting cash requirements for the next twelve months[215](index=215&type=chunk) Contractual Obligations as of June 30, 2023 (in thousands) | Obligation | Total | Payments Due < 1 Year | | :--- | :--- | :--- | | Term loan | $2,029 | $2,029 | | Promissory note | $5,000 | $625 | | Facility operating leases | $1,379 | $415 | | Purchase obligations | $3,455 | $3,455 | | **Total** | **$11,863** | **$6,524** | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=44&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes in its market risk exposure during the six months ended June 30, 2023, compared to the disclosures in its 2022 Annual Report on Form 10-K - There have been **no material changes** in the company's market risk during the six months ended June 30, 2023[219](index=219&type=chunk) [Item 4. Controls and Procedures](index=44&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of June 30, 2023 - Management concluded that as of June 30, 2023, the company's disclosure controls and procedures were **effective**[220](index=220&type=chunk) - **No changes** in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[222](index=222&type=chunk) [PART II. OTHER INFORMATION](index=45&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section covers legal proceedings, updated risk factors, and a list of exhibits filed with the report [Item 1. Legal Proceedings](index=45&type=section&id=Item%201.%20Legal%20Proceedings) The company states it is subject to various legal proceedings in the ordinary course of business but believes that none are expected to have a material adverse effect on its financial condition or results of operations - The company is **not aware of any legal proceedings** that would have a material adverse effect on its business, results of operations, or financial condition[224](index=224&type=chunk) [Item 1A. Risk Factors](index=45&type=section&id=Item%201A.%20Risk%20Factors) A material update to risk factors highlights substantial doubt about the company's going concern ability due to insufficient cash and recurring losses - A key updated risk factor is the company's **ability to continue as a going concern**, with recurring losses and cash burn raising **substantial doubt**[226](index=226&type=chunk) - The company's current cash is **not sufficient** to fund operations for the next 12 months, requiring additional capital with **no certainty** of availability on acceptable terms[226](index=226&type=chunk)[227](index=227&type=chunk) [Item 6. Exhibits](index=46&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including amendments to the At the Market Offering Agreement and the Loan Agreement with Pacific Western Bank, as well as certifications by the CEO and CFO - The report includes **several filed exhibits**, such as amendments to its ATM offering agreement, loan agreement, officer certifications, and Inline XBRL financial statements[229](index=229&type=chunk)

Financial Data and Key Metrics - Record quarterly revenues of $4.1 million, up 61% compared to the same period last year [6] - Gross profit for Q1 2023 was $2 million, representing a gross margin of approximately 49%, up from 47% in the prior year [16] - Loss from operations in Q1 2023 was $4.4 million, compared to $4.2 million in the prior-year period [33] - Cash used in operating activities in Q1 2023 was $4.2 million, with a cash balance of $16.3 million as of March 31, 2023 [33] - Operating expenses for Q1 2023 were $6.4 million, up from $5.4 million in Q1 2022, primarily due to the acquisition of HMC and increased marketing activities [43] Business Line Performance - EksoHealth delivered $4 million in revenue in Q1 2023, driven by multi-unit orders with large network operators, including the second-largest EksoNR order ever [26] - EksoWorks revenue decreased by $0.6 million in Q1 2023, with a focus on transitioning towards volume purchases from large customers in industries such as construction, manufacturing, and green energy [49] - The newly acquired HMC business unit contributed modestly in Q1 2023, with expectations for stronger contributions as the year progresses [35] Market Performance - EMEA region grew 67% compared to Q1 2022, with the first Ekso Indego personal device sold in Europe during the quarter [27][28] - The company expanded its distribution network in EMEA through the acquisition of HMC, adding a commercial resource and strengthening partnerships [50] Strategic Direction and Industry Competition - The company is focused on driving sustainable growth across the continuum of care, leveraging its EksoHealth and Ekso Indego product lines [25][31] - Integration of HMC is progressing smoothly, with plans to merge market-leading technologies to deliver lower extremity rehab and mobility solutions [32] - The company is expanding its product development pipeline into the orthotic and prosthetic (O&P) industry, forming strategic relationships with key partners like Vanderbilt University [29] Management Commentary on Operating Environment and Future Outlook - Management highlighted strong demand for EksoHealth devices, including EksoNR and Ekso Indego, driven by the success of the commercial strategy [41] - The company anticipates continued growth in EMEA and plans to strengthen its sales and distribution network in the region [36][50] - Supply chain challenges have caused margin compression, but management expects improvements as the supply chain stabilizes [40][52] Other Important Information - The company reestablished its partnership with SoldierStrong, a charitable organization supporting veterans, and donated its 30th robotic exoskeleton to a VA Medical Center [10][11] - The cumulative conversion and renewal rate remained strong at 81%, with $1.4 million of contracted unrecognized revenue under the subscription model [8] Q&A Session Summary Question: Contribution of Indego in Q1 2023 - The contribution from Indego in Q1 2023 was relatively modest, but the company expects stronger contributions as the year progresses [35] Question: EMEA Growth and Sales Personnel - The company has a strong team in EMEA, with additional resources added through the HMC acquisition, and feels adequately resourced to support growth in the region [50] Question: Multi-Unit Orders in the US - The company is seeing more multi-unit opportunities in its pipeline, both in the US and internationally, and continues to grow relationships with network operators [51] Question: Potential for Margin Expansion - Management expects further margin expansion through supply chain improvements and cost reductions, with most supply chain challenges peaking or behind them [52] Closing Remarks - The company thanked employees and shareholders for their contributions and support, expressing optimism for continued growth and momentum [56]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 ...